STING1 and neoplasm: When combined with therapeutic vaccination, a STING agonist can highly enhance the frequency of both peripheral and intra-tumoral antigen-specific effector CD8 T cells along with increased cytotoxicity, resulting in a prolonged control and slower growth of tumors in several tumor models (58, 59).